Earnings Call: Q3 2020

Nov 9, 2020

Ladies and gentlemen, thank you for standing by, and welcome to the Q3 2020 Fulgent Genetics Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that today's conference is being recorded, 9th November 2020. I would now like to turn the conference over to your first speaker for today, the Head of Investor Relations, Ms. Nicole Bauschiere. Thank you. Please go ahead, ma'am. Great. Thanks very much. Good afternoon, and welcome to the Fulgent Genetics' 3rd quarter 2020 financial results conference call. On the call today are Ming Choe, Chief Executive Officer Paul Kim, Chief Financial Officer and Brandon Perthes, Chief Commercial Officer. The company's press release discussing its financial results is available on the Investor Relations section of the company's website, bulgargenetics.com. An audio replay of this call will be available shortly after the call concludes. Please visit the Investor Relations section of the company's website to access the audio replay. Management's prepared remarks and answers to your questions on today's call will contain forward looking statements. These forward looking statements represent management's estimates based on current views and assumptions, which may prove to be incorrect. As a result, matters discussed in any forward looking statements are subject to risks, uncertainties and changes in circumstances that may cause actual results to differ from those described in the forward looking statements. The company assumes no obligation to update any of the forward looking statements it may make today to reflect actual results or changes in expectations. Listeners should not rely on any forward looking statements as predictions of future events and should listen to management's remarks today with the understanding that actual events, including the company's actual future results, may be materially different than what is described in or implied by these forward looking statements. Please review the more detailed discussions related to these forward looking statements, including discussions of some of the risk factors that may cause results to differ from those described in these forward looking statements contained in the company's filings with the Securities and Exchange Commission, including the previously filed 10 Q for the quarter ended June 30, 2020, which is available on the company's Investor Relations website. Management's prepared remarks, including discussions of earnings and earnings per share, contain financial measures not prepared under exception in the United States or GAAP. Management has presented these non GAAP financial measures because it believes they may be useful to investors for various reasons, but they should not be viewed as a substitute for or superior to the company's financial results prepared in accordance with GAAP. Please see the company's press release discussing its financial results for the Q3 of 2020 for more information, including the description of how the company calculates non GAAP earnings and earnings per share and a reconciliation of these financial measures to income and income per share, the most directly comparable GAAP financial measure. With that, I'd now like to turn the call over to Ming. Thank you, Nicole. And thank you for joining our call today to discuss our Q3 2020 results. We view the highlights from our Q3 before handing over to our Chief Commercial Officer, Brandon Curtis, to provide updates on our commercial success and the go to market strategy. And finally, Paul will discuss our financial results and outlook in detail. The COVID-nineteen pandemic has continued to challenge both our health and our way of life this year. At 4 gs, we took early action to leverage our technology platform to a comprehensive cost offering to meet the increased demand for reliable testing solutions. While we have come through a long way together in our effort to combat this pandemic, we still have a long road ahead of us as we look to return to normalcy. We'll continue to do our part at the Fusion to help to get testing solutions to individuals and organizations that need them so that business school, sporting events, travel and social engagements can resume safely. Our record growth in the Q3 is true testament to the scalability of our technology platform. We discussed last quarter how the often seeing events of this pandemic has really proven FOGEN Genetics is as a company and the results we discussed today to go one step further to demonstrate how the platform is truly unmatched in the genetic testing industry. With the modest level of investment in the infrastructure and headcount, we were able to grow our test volume almost 15 times or 5,000 percent over that in the Q3 of last year and by more than 5 times or 500 percent of that in the Q2 of this year. At the same time, our gross margin improved by 19 percentage points sequentially with the operating expense only roughly doubling on a GAAP basis, which translates into operating income of 63 $500,000 and a record adjusted EBITDA of $67,400,000 This growth and the profitability were made possible by the efficiencies we have across our business from our life operations and our information management and the reporting system to have our own proprietary biochemistry and reagents to our enhanced reimbursement capabilities and our system who have covered a significant amount of ground and signing a number of substantial agreements, securing large volume of tests in the quarter ahead. We have grown our headcount from 151 at the beginning of 2020 to approximately 500 employees' income to softness today. None of this was done overnight and we believe we have strong foundations on which to grow our core business in the years ahead. To that end, we believe the investment we made to build our COVID-nineteen test initiatives will continue to benefit our business in long term. There are 3 particular areas of strength I would like to elaborate on, especially in the quality and the scale of our customer base. The traction we have from insurance provider on reimbursement and we haven't seen our commercial initiatives at home test offering, PICTRA Genetics. On the customer front, we have made a meaningful strike in signing large agreements with the range of commercial organizations, municipalities and the management institutions. Some of these, we have now publicly, but we have 1 number of additional strategic customers that we have not publicly disclosed. Many of these institutions have never heard of 4th genet before the pandemic And now we have proven our ability to deliver large volumes of high quality tests in a quick and efficient manner. We have seen increased volume of our course genetic tests on number of new customers. Brandon will elaborate further on some of these customer dynamics. 2nd point I want is on the reimbursement. Historically, our customers have predominantly been cash paying customers, which very little given our rapid expansion in new customers combined with quarterly test volume, we should now exceed the 1 immediate test. This has accelerated the need of reimbursement agreement with insurance providers. We believe that having this reimbursement agreement in place will continue to drive business from the customers in a way that we haven't seen prior to the pandemic. The 3rd areas I want to highlight as an avenue of durable growth is our consumer offering, Xtra Genetics. We launched the platform in 2019 to make a clinical breadth genetic testing available to individuals in the comfort of their homes without need to visit a doctor office. Our original offering consists of 3 tests, carrier screening, neuro screening and adult wearables. We added at home COVID-nineteen test service to the platform in late June. And since then, we have seen very strong demand for this at home test. As we stated repeatedly on previous earnings calls. The cornerstone of our business is our technology and its flexible platform, which will allow us to develop, validate, customize and launch our products and services. The investment made in our technology stretch back almost a decade and enable all the effects of our business, which produce notable efficiency and scalability. We plan to getting even more aggressive in our continued investment technology into further separate us from our peers in the future. We welcome the news about the very promising vaccine development from Pfizer today. Since we have made a 2,500,000 dollars investment in a private company called Boston Molecules during this quarter. We believe this could enhance and lead 4GIN Genetics to develop and enhance our neutralizing antibody test for COVID-nineteen immunity, especially for the people who get the vaccine or patients recovered from COVID-nineteen. In the meantime, we continue to add content and add additional tests for our core business to address the growing needs for the genetic testing market. In sum, armed with our technology, the transformation of our oral business and that we expand the capabilities will allow us to make a notable footprint in the screening and the genetic testing market in the years ahead. With that, I'll turn the call over to Brandon to dig into more about the customer dynamic we are seeing in this quarter and elaborate on the long term drive for our momentum. Brendan? Thanks Ming. As Ming mentioned, we delivered more than 1,000,000 reports during the Q3, an almost 50 fold increase year over year and an almost 5 fold increase sequentially. Despite massive increase in volume that we experienced, we delivered results to our customers without any issues and with best in class turnaround time for RT PCR results. During the Q3, greater than 90% of our COVID-nineteen results were delivered within 24 hours, some as fast as 8 to 10 hours, which our customers would agree is pretty incredible. This is all possible because how we built this company and how we have leveraged technology and operational excellence. We are a genetic testing laboratory built by engineers, founded in technology. For years, we described ourselves as a technology company providing clinical genetic testing, and we have continually emphasized the power of our technology platform. In the Q3, I think we have proven it in practice. Not only that, we have done it the hard way, building our business organically from the ground up. Before we get into our COVID-nineteen business, I would first like to highlight the strong quarter we had in our core genetic testing business. While we projected a slight decline in our core business due to the pandemic, it has rebounded much faster than we thought and grew 57% sequentially from a revenue standpoint. This has been in large part due to our ability to win new clients while maintaining relationships with existing clients, even as some of those clients experienced lower test volumes amid the pandemic. To further emphasize this point, we looked at our top core business customers in the Q3 of this year and compared it to the Q3 of last year. Of those top customers, we're new. This demonstrates how our core business has continued to strengthen with new customers we've been winning. Both new and existing clients are increasingly taking advantage of our expanded product portfolio, which now includes almost 19,000 tests. Customers are using Fulgent for hereditary cancer, cardiovascular genetics, neurological genetics, reproductive health and other newer tests that we've launched in the last 12 to 18 months. At this point, we have one of the largest, most diversified genomic test menus in the industry, and we plan to continue to launch new tests. Switching to our COVID-nineteen business. During the Q3, we brought on almost 80 new clients, representing thousands of individual users. These wins included drive through operations for the counties of Los Angeles, Alameda, Orange, Santa Clara, San Bernardino, Miami Dade, the state of Utah, the city of Long Beach and others. In addition to the Hughes drive thru operation wins, we announced our partnership with New York City Health and Hospital and their Test and Trace program for K-twelve testing, both on-site and at home. Regarding the on-site testing for New York City, we now have over 60 pairs of boots on the ground to help with school site operations. This program went live in October, and we are now collecting thousands of samples per week throughout New York City. We also announced in the 3rd quarter that we won a competitive bid for the entire state of Ohio prison system to provide testing for their 12,000 employees. In addition to the agreements we announced, there were a few other public announcements from our clients describing their partnerships with Fulgent. Those included Northwestern University using our pitcher at home test for their students for a return to school program and the PAC-twelve conference using our test for athletic programs and sports officials. While we haven't announced all of our wins, we will continue to publicly announce large strategic wins to the extent we can. Overall, I am very pleased with the execution of our sales team in the quarter as we consistently won in competitive opportunities. Clients are choosing Fulgent COVID testing offerings for a variety of reasons, including our rapid turnaround time, supply chain availability, capacity, EUA approvals, our technology platforms and user friendly systems. I'd like to spend just a few minutes to discuss each of these in detail. Regarding turnaround time, it's been widely publicized that labs have struggled with turnaround time and patients have experienced delays receiving test results. Initially, some labs are taking 5 to 7 days and sometimes longer to return results to patients. However, since the day we launched our COVID-nineteen test, we have delivered results within 24 hours. And even with the explosive growth we have seen, we have continued to improve. This has really been important for patient care and contact tracing and has been a huge differentiator for Fulgent. 2nd, supply chain. While many labs have seen shortages in critical supplies, such as reagents, transportation media and swabs, we've had no such issues. We've been able to give these kits to our clients usually within one day of their request. We remain well stocked to continue to fuel our growth plan. 3rd, our capacity. At this time, between our headquarters in Temple City, California and our new lab in Houston, Texas, we have a maximum daily capacity of 60,000 tests per day. This has allowed us to serve our existing business, win new accounts and continue to build a robust pipeline of new opportunities. At the same time, our clients are confident using Fulgent volume. As needed, we could quickly scale to handle 80,000 tests per day and more. 4th, our 2 EUA approvals. Getting EUA for our standard physician administered RT PCR test was critical as it served as a validation and stamp of approval for our quality. It has been important when it comes to winning RFPs and government contracts. Our second EUA was for our Pitcher at home test, which has been instrumental for our growth. We are one of a limited number of providers with its approval and at home testing is proven to be a differentiator and an important testing tool to help in the fight against this pandemic. Furthermore, we have submitted an EUA for our next generation sequencing based COVID-nineteen test, which is still pending with the FDA. Last, but certainly not least, the technology platforms we have built to support COVID-nineteen testing have been critical to our success. We have discussed these in detail on previous calls, but the platforms include the Folgit Enterprise and Folgit Community, which support corporate testing and drive through testing, respectively. These have made managing large volumes of tests much easier for our clients and have connected them to the Fulgent platform, creating deep relationships that go just beyond being an RT PCR test provider. Our clients are using our applications to run their daily operations. One other point of differentiation on our COVID-nineteen test offering, which we announced in September, is that we will give our clients an option to add influenza A and B. This is done on the same sample with no need for clients to make any collection protocol changes. In the future, we plan to add additional pathogens to our panel to provide comprehensive testing for patients with respiratory infections. It is not just influenza and COVID-nineteen that can cause respiratory infections. In addition to those, there are approximately 500,000,000 non influenza respiratory infections occurring annually. The symptoms of respiratory infections, including COVID-nineteen, are very similar and it can be difficult to differentiate the best treatment plan. A comprehensive panel of pathogens can help provide an accurate diagnosis, therefore allowing for a more personalized treatment plan. The success we have had with COVID-nineteen testing has allowed us to expand our go to market strategy. More so than ever, we are working closely with the payers and are making progress becoming an in network provider. During the Q3, we filed over 590,000 insurance claims, an increase of almost 9,000 percent over Q2. With this increased visibility with the payers, we can now tell the Folgen story and show the value of having our services in their network. As Ming mentioned, COVID-nineteen has also served as a springboard for our consumer initiated platform, Pitcher Genetics. Since obtaining the at home EUA from the FDA and formally launching our Pitcher test for COVID-nineteen in mid June, we have had significant demand. We believe Pitcher is now a well known and rapidly growing brand that will continue to deliver for us going forward as we expand the number of tests being offered on the platform. It is quite common for families to have to wait many weeks, even months to see a pediatric genetic specialist, and usually the first step is order a genetic test. We see a day where families can get the testing they need through Pitcher ahead of the visit and then spend the time with the specialists discussing results, prognosis, treatment plans, etcetera. Lastly, we have seen COVID-nineteen bring us many, many new clients. These include huge hospital systems, some of the largest specialty care clinics, government agencies, large companies, etcetera. Our relationships with these clients are very deep, and many will be able to use our core products and services in the future. To that end, during the Q3, we engaged with 1 of the largest biotech companies in the United States in a competitive bid for their employee testing. I'm excited to announce today we have won the opportunity. Fulgent will test many thousands of their employees weekly on our enterprise platform from their several locations across the United States. Testing is expected to begin January 2021 and will continue for at least 18 months. Are very happy to partner with such an amazing company, and we look forward to helping keep their workforce safe. Switching gears, I'd like to briefly touch on the opening of our Houston lab, which we announced in August. This facility is a great example of the power and portability of the Fulgent technology platform. We are able to launch this high capacity lab in record time by building on top of our foundational Fulgent technology. The Houston lab is underway from the Texas Medical Center, the largest medical center in the world. This puts our new lab in close proximity to an amazing talent pool as well as world renowned cancer centers and pediatric hospitals. Folsom Houston will soon serve as a fully operational second site. And finally, I'd like to take a moment to clarify some confusion that has existed regarding the types of COVID-nineteen tests available and how they're intended to be used. There have been some attention grabbing headlines regarding cheap and fast antigen testing. We want to be clear that antigen testing is not a replacement for RT PCR. In fact, it's hardly a competitor. Antigen testing is intended to be used for only symptomatic patients within 7 days of symptom onset. However, data presented in antigen EUAs show that at day 67, the sensitivity drops measurably and positive cases are already being missed. This would lead to false negative results, which are particularly troublesome. The EUA of several antigen tests think that a negative result should be followed up by RT PCR and the CDC has been clear that RT PCR is the gold standard to detect SARS CoV-two. RT PCR provides the highest level of sensitivity and specificity. Simply put, it's the best test. For early detection, screening, testing of asymptomatic and pre symptomatic, RT PCR is currently the only viable option. Coupling the gold standard test with our industry best turnaround time make the Folgent solution a powerful tool to fight against the spread of COVID-nineteen. I would like to now turn the call over to Paul Kim, who will walk you through our Q3 financial performance. Thanks, Brandon. 3rd quarter revenues totaled $101,700,000 an organic increase of 883 percent compared to the Q3 of 2019. Billable tests in the quarter totaled 1,040,000 growing almost 5,000 percent over Q3 of last year. The vast majority of this volume was from our business related to COVID-nineteen. And though the majority of volume and revenues in the quarter were related to COVID, we saw a sharp rebound in our traditional genetic testing business. Compared to Q2, our traditional genetic testing business grew by more than 57%. The breadth of our customer base was impressive during the quarter with over a dozen companies contributing over $1,000,000 of revenues. Our ASP in the Q3 was $98 higher than the $96 we saw in the Q2. The increase is attributable to the vast majority of our tests now going through reimbursement and our favorable payment experience to date. COGS per test for the quarter was $25 an improvement of approximately 42% compared to the 2nd quarter. Gross margin improved almost 19% points sequentially. The primary reasons for the decrease in cost per test were continued automation efficiency and in general the utilization of our technology platform. Turning over to operating expenses. Total GAAP operating expenses were $11,900,000 for the 3rd quarter, up from $6,900,000 in the 2nd quarter. Non GAAP operating expenses totaled $9,200,000 up from 6% in the Q3. As Ming mentioned, we made a small investment in a company called antibody and antigen testing capabilities as well as assisting in the developing landscape for therapeutics. This translated to approximately $2,600,000 charge below operating expenses. Non GAAP operating margin improved approximately 44 percentage points sequentially to 65.5%. We continue to make meaningful investments across all our departments in the quarter, but our top line outperformance and increasing operating efficiencies are out stripping our investments into our business. Based on our profits, we recorded a 23% tax rate in Q3. This rate releases our valuation allowance on our deferred tax assets and incorporates our projected annual tax rate for the year. Adjusted EBITDA for the Q3 was $67,400,000 compared to $3,000,000 in the Q3 of 2019. On a non GAAP basis and excluding equity based compensation expense, income for the quarter was $49,000,000 or $2.08 per share based on 23,500,000 weighted average diluted shares outstanding. The 3rd quarter was $104,000,000 in cash, cash equivalents with no debt. During Q3, we had an equity shelf program in place, which enabled us to sell approximately 1,300,000 shares in the open market, raising $42,300,000 in cash. With the momentum in our business revenues of $17,800,000 from a customer who wanted to secure their position in delivering our services in the future. Moving on to our outlook, we see the second half of twenty twenty as a continuation of our inflection point in our business, which began last quarter. In addition to the momentum we had with our COVID test, our core genetic testing business and sequencing as a service business have remained strong. We have expanded our partnerships on the reimbursement front and are seeing high demand for tests across our picture platform. Most of all, we're seeing our customers appreciating the clear differentiation by the application of our technology platform. And based on the explosive demand we're continuing to see from the market and the quality of our customer base, we believe the 4th quarter will cap what has been a transformative year for our company. We now project test volumes for the year to be well over $2,000,000 which translates into over $235,000,000 in revenues. More specifically, we anticipate Q4 revenues to be at least 110,000,000 dollars With a powerful leverage in our model, this translates into GAAP net income and excluding stock based compensation, we expect non GAAP net income of approximately $100,000,000 or approximately $4 per share for our shareholders in 2020. As a final note, we appreciate the patient shareholders who had faith in our business over the past 4 plus years and look forward to sharing updates our business in future quarters. Operator, now you can open it up for questions. Thank you. Our first question is from the line of Rachel Lansdowne from Piper Sandler. Your line is now open. Great. Hi. This is Rachel on for Steve. Congrats on the nice quarter you guys. Thank you. Yes. So that was a substantial guidance increase. Can you just walk us through how we should think of the core business versus COVID revenue in that guide? And then a little more forward thinking, can you walk us through what you guys are thinking about for testing demand over the next year or 2 with an effective vaccine on the market following that news we saw this morning? So I'll take the first part of that question on the core business and then I'll turn it over to Ming followed by Brandon as to their thoughts on the landscape and the developments on the vaccine use from today. So on the core business, we were extremely pleased with how the core business performed during the quarter. As I indicated, the core business grew 57% sequentially, which translates into approximately 20,000 tests and revenues of approximately $10,000,000 to $11,000,000 which is at a record for the company. It's at consistent levels with what we posted in the Q3 of 2019, which was a high point before this quarter. Then looking out into Q4, we anticipate that our volume for the core business to be approximately 25,000 with revenues being in the low teens. And the core business is performing better than we had hoped and that's because we've signed on many new customers. We also added content to our genetic testing menu across the board, whether it be cancer, women's reproductive health or pediatrics. And as you remember, we ended last year with approximately $32,000,000 of revenues, all non COVID. And before COVID hit, we guided The Street to $40,000,000 of business for the year. And then during the earlier on part of this year in March, April May, during the 1st lockdown, that impacted the core or the genetic testing business across the industry. But because of the additional capabilities that we made in terms of reimbursement, the great traction that we've seen in reimbursement, because we've signed on so many more core customers and we've proven ourselves for the capabilities and the efficiencies that we've had in the lab, we've seen a tremendous uptick in our core business in the back half of this year. So we're still on track to meet the $40,000,000 but that $40,000,000 of business that we had in the core business hasn't been linear. We had a lull in the springtime of the year, but we came back roaring in the back half of the year. So what that tells us is if we continue on with the momentum and our capabilities as company, our outlook for our core business in 2021 should be very, very favorable. And I'll turn it over to Ming who can give commentaries on the vaccine. I think in terms of vaccine development, we welcome the news of the well vaccine development because we do see that continues the demand for the 4GIN Genetics to provide a faster, quicker and cheaper test in terms of diagnostics, the COVID-nineteen test. In addition, as the vaccine developments come in, they are adding additional requirement for the test, faster and cheaper and quicker and more accurate test. For the antibody test, neutralized antigen test. So I think this is to create the new opportunity for 4G Genetics in this space. I do not believe the COVID-nineteen will go away easily. But as long as there is a requirement in this space, Photogen Genetics will be there to provide faster, quicker and more accurate tests to responses of pandemics. And Brandon can give you some of the details. Yes, certainly. Hey, Rachel, Brandon. We continue to believe that the COVID-nineteen testing is quite durable. We think it's going to stretch well into 2021. At these same levels, who knows, we don't have that crystal ball, no one does, right. But we think we're extremely well positioned to be a major player in this market. So we think it's going to be around with us for a while. At these levels that we are forecasting in Q4 and Q1, we will see, right? But should testing even begin to slow down a little bit, the way we position this company with our technology platforms, we're going to continue to take market share from other people, right? A lot of our wins have been organic. That's a fact. At the same time, we are taking market share from other people. So we think we can play a dominant role in the testing. We think it's quite durable. And I think the platforms we've built, the turnaround time, the systems, I think we're going to be a player for deep into 2021. Great. Thank you for all that color. Next, can you just give us some more details on some of the contract terms that you guys have won? For example, what are the terms and how long are they? And do you have any exclusivity agreements? All of the above, Rachel. So some are exclusive, some are not. We look at the contracts, they range from month to month to 24 months. I think our longest one we signed so far has been 24 months. These contracts have been with government agencies, municipalities, big companies, you name it, colleges, sports conferences, and we're done, Rachel. So a lot of these contracts are laboratory services agreements. Like I said, some have exclusivity, some don't. And most of them, I would say, a majority of them do have some legs to them to where they're going to stretch many months and deepen into 2021. Great. And then last question for me is that you guys have quite a bit of cash following these COVID-nineteen tailwinds. Can you talk about your plans for using the money to invest in the business? Thanks. Sure. So that's an excellent question. Yes, we generated a lot of cash based on the momentum that we had in the business. And we believe in capping off this year, it would demonstrate several things. 1, the viability and the provenness of our business model. 2, the efficiency, as well as the scalability of Fulgent Genetics. And we believe in the our traditional genetic testing space or in the wider screening market that we will be one of the consolidators to take a look at businesses and technologies that we can incorporate or potentially incorporate as our own to enhance our technological lead in addition to making a stronger company. Yes. To add Paul's points, we'll continue to invest carefully to enhance our position in terms of our technology and also our market positions. Our next question is from the line of Erin Wright of Credit Suisse. Your line is now open. Great, thanks. You've always obviously been very nimble here with the COVID response, which has been impressive. But I guess how can you repurpose some of the capacity expansion in like a post vaccine kind of post COVID sort of world? How does that fit in into your longer term plan from a capacity standpoint? Thanks. Erin, this is very good questions. As I mentioned, the COVID-nineteen is not going to be goes away completely. Our investment in terms of capacity, it is always the multiple use. We're not only to use our test for the COVID-nineteen, but that we also our other genetic tests. As we continue seeing the increase for the demands. We increased our automation. These automation machines can use for multiple different purpose. As you recall, all our lab management system and software has developed in house. So we definitely could program or repurpose some of those equipments getting into the mix of our complete automation for the lab automation. Aaron, from a numbers perspective, this is Paul. So you can break out the investments that we made as well as the spending in a couple of different buckets. So number 1, our total fixed assets and the equipment purchases for the year is going to be between $10,000,000 $15,000,000 And then we have added a number of people to the organization, but not all of them are employees. Many of them are consultants in the operational lab area. So if you take a look at the amount that we're spending for COVID versus what COVID has brought us just for this year, we're going to be generating approximately $200,000,000 of COVID business on top of massive profits. We've already gotten massive returns on those investments. So COVID is not going to go away at the end of 2020. We see these contracts going deep into 2021. We believe we'll have material level of COVID business. So whatever investments that we're making, we believe that we'll have immediate returns on that. And then from an operational sense, we can quickly deviate the resources into other areas that we believe will be fruitful for the company. Okay. That's helpful. And then on the reimbursement front, obviously, we had favorable reimbursement for COVID testing, and CMS has extended that through late January. How long do you think that lasts thereon? And do you feel comfortable I assume you feel comfortable now based on sort of your prepared remarks in terms of your turnaround time to meet their 2 day requirements? Yes, Rachel sorry, Aaron. We were happy to see what they did actually to reward those laboratories that can actually deliver on turnaround time. We think that's incredibly important. When it comes to contact tracing, the turnaround time needs to be 24 hours or less for this test to be as powerful as possible. Their decision to do that, we hope that that reimbursement rate will continue deep into 2021. We'll see how it plays out. I think as Paul mentioned, we do have some additional leverage in our COGS there. So we're also on the private side as well, not just the Medicare and Medicaid from the CMS perspective, the private side also is a satisfactory reimbursement. So we hope that it will stick around. We think it will. And yes, in terms of meeting the turnaround time to get that extra reimbursement, we are incredibly confident in our abilities to do that. And Aaron, remember, the COVID-nineteen test started at $50 Most of the lab could not survive with that price, the CMS increased the rate. And most labs could not meet the response time, the CMS gave the 2 rates, dollars 100 for the 24 hours 48 hours response time or the $75 if we could not meet the 48 hours response time. Fulgent Genetics is not positioned well positioned to meet the time challenges, but also we're able to perform in this market at any price to compete in this market. I think the 4 gs genetics, when we get in, we're not the highest provider. We provide the low cost competitive bid in all our efforts. Not only will Windows bid effectively, but also we are able to deliver the bottom line as the results we deliver today. We will continue to enhance our position in this area because of our technology, because of our biochemistry and because of our pipelines. And just to give you a point of reference on the reimbursement, we had $90,000,000 of accounts receivable at ninethirty. As of today, we collected on more than $60,000,000 of that $90,000,000 balance. And the reason why we've been able to get that kind of collection is because of the efficiency as well as the enhanced capabilities that we have as a company in the area of reimbursement. And as Ming indicated, the CMS reimbursement rate is $100 and starting January 1, it stays at $100 as long as you're able to meet the turnaround time. But because our turnaround time is just getting quicker with the additional volume, we don't have a whole lot of doubt whether we can meet that threshold starting on January 1, 2021. Okay. All right. Thank you. Next we have Kevin DeGeeter of Oppenheimer. Your line is now open. Great. Thanks, guys. I want to revisit genetic testing and, Paul, some of your comments with regard to how to think about that portion of business for the year. I believe if I heard you correctly, you feel comfortable kind of at that $40,000,000 reported revenue for genetic testing for the year. If our math is right, that suggests somewhere around $15,000,000 for 4Q or another 40% sequential growth in that business on top of the 57% in the current quarter. So can you just comment a little bit more about what's driving that? What portion of the business? Is it hereditary cancer? Is it a carrier? And how should we think about, if our math is right, that 15 $1,000,000 as a good baseline to think about building growth into 2021? Yes, that's an excellent point. So we are on track with our original guidance, which is quite a feat because a lot of the diagnostics companies, 2020 was essentially a throwaway year. But oddly enough, it seems like we're on track to meet the original guidance even before COVID has hit. And the reason why it's accelerating in the back half of the year is because during the lockdown period and even with the momentum of the COVID business, we continue to sign on additional pediatrics. And we believe things open up more and should people get more comfortable going to clinics, having the genetic the comfortness of returning to some kind of normalcy for the genetic test, but that will just open up the doors for even more enhanced business, for our core NGS testing. And I'll turn it over to Brandon who can give more commentaries, both in terms of the number of customers, the quality of the customers, as well as the size of programs that they're thinking about for our core business. Hey, Kevin. Yes, I think in the script I read, customers in Q3 this year versus last year and actually got a text who said I cut out a little bit, so I'll reemphasize what I said. In the Q3 of this year, greater than half of those customers were new, right? We looked at our largest customers in Q3, more than half of those were new this year. So Paul is right, we've continued to bring on new customers, we continue to win business. These customers are not running at full speed. Let's make no mistake about it. We're still not back open like we need to be, we want to be. But this growth has been fueled by continuing to win new customers. So, we think when our expanded portfolio of customers is running at full speed, when they're seeing the same number of patients they saw pre pandemic, could be a pretty powerful turning of point for our company. Kevin, the last thing is on the cost side. When we talked about the efficiencies that we have for COVID, but our core business, that's also gaining a lot of benefit from the automation and the efficiency, meaning that our COGS per test during Q3 on a full GAAP basis was $25 On a non GAAP basis, it's even lower than that. But that includes our core genetic tests on top of COVID. So you can just estimate what our cost structure is, whether it be for COVID or non COVID. We're not going away anywhere and we believe we can compete in any kind of environment. Okay, great. Now that's super helpful. And as we think about continued menu expansion, you did call out some opportunities with regard to infectious disease side of the portfolio, but are there important or meaningful menu expansion opportunities in genetic testing as you think continue to fuel this type of growth to existing customers as they expand the breadth of their ordering into a broader menu for genetic testing? Well, Kevin, if we throw away $100,000,000 we can easily buy $20,000,000 or $30,000,000 of business, okay? But that's not the way we do, okay? Definitely, we see the business opportunities as we walk into the each opportunities. We need to make sure we have a sound business model. We need to make sure it is beneficial to our clients. But in addition, we need to make sure that we also provide returns to our shareholders. So with this organic growth, I think we are going to focus in the area of cancer, in the advanced cancer treatment, how do we do to provide the precision medicine. FourGen's continue to invest in these areas. We will introduce the products in this area. Due to the COVID-nineteen, I think it slowed down a little bit our introduction in this kind of products. But definitely, that's the areas that we will be focused on. Yes. I think we've been on a test launch craze for the last year, 1.5 years. I mean, now the test menu is over 19,000 tests. So we continue to pump out new tests. We think that's important looking at different disease, different phenotypes. So yes, we continue to develop new tests. I guess sort of tactically speaking, a couple of weeks ago, we did launch a pharmacogenomics test, which we're pretty excited about. We have not played a major role in pharmacogenetics in the past. But with our technology, our capture set, our pipelines, we were able to develop that pretty quickly. So we will be bringing the market, which will help in personalized therapy and drug treatment. All very exciting. Thank you for taking my questions. Thanks, And there are no further questions as of this time. I will now turn the call back to Nicole for any final comments. Thanks everyone for joining our call today. We look forward to keeping in touch with you in the days weeks ahead. Have a great day. Ladies and gentlemen, this concludes today's conference call. Thank you all for participating. Enjoy the rest of your day. Keep safe and you may now disconnect.